• While the findings indicated no want for a brand new vaccine to deal with the brand new strains, Pfizer and BioNTech mentioned they might reply if there was proof that the variants may defeat their present vaccine.

AFP

PUBLISHED ON JAN 28, 2021 01:52 PM IST

Pfizer and BioNTech, makers of a Covid-19 vaccine, mentioned on Thursday that their product is efficient towards coronavirus variants which have emerged in Britain and South Africa.

In a press release, the 2 firms mentioned the “small differences” detected in exams evaluating the unique virus and the latest variations “are unlikely to lead to a significant reduction in the effectiveness of the vaccine”.

While the findings indicated no want for a brand new vaccine to deal with the brand new strains, Pfizer and BioNTech mentioned they might reply if there was proof that the variants may defeat their present vaccine.

They would proceed to observe their vaccine’s “real-world effectiveness”, together with towards new strains, they mentioned.

“Pfizer and BioNTech believe that the flexibility of BioNTech’s proprietary mRNA vaccine platform is well suited to develop new vaccine variants if required,” they mentioned.

Daily world deaths from Covid-19 topped 18,000 for the primary time Wednesday, with vaccines seen as the one actual likelihood of returning to some type of normality.

Close


Follow us on Google News

VNAP News Portal